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Objectives. To investigate the added value of assessing transcripts for the long cAMP phosphodiesterase-4D (PDE4D) isoforms,
PDE4D5 and PDE4D9, regarding the prognostic power of the ‘CAPRA&PDE4D7’ combination riskmodel to predict longitudinal
postsurgical biological outcomes in prostate cancer.Patients andMethods. RNAwas extracted from both biopsy punches of resected
tumours (606 patients; RP cohort) and diagnostic needle biopsies (168 patients; DB cohort). RT-qPCR was performed in order
to determine PDE4D5, PDE4D7, and PDE4D9 transcript scores in both study cohorts. By RNA sequencing, we determined the
TMPRSS2-ERG fusion status of each tumour sample in the RP cohort. Kaplan-Meier survival analyseswere then applied to correlate
the PDE4D5, PDE4D7 and PDE4D9 scores with postsurgical patient outcomes. Logistic regression was then used to combine the
clinical CAPRA score with PDE4D5, PDE4D7, and PDE4D9 scores in order to build a ‘CAPRA & PDE4D5/7/9’ regression model.
ROC and decision curve analysis was used to estimate the net benefit of the ‘CAPRA & PDE4D5/7/9’ risk model. Results. Kaplan-
Meier survival analysis, on the RP cohort, revealed a significant association of the PDE4D7 score with postsurgical biochemical
recurrence (BCR) in the presence of the TMPRSS2-ERG gene rearrangement (logrank p<0.0001), compared to the absence of this
gene fusion event (logrank p=0.08). In contrast, the PDE4D5 score was only significantly associated with BCR in TMPRSS2-ERG
fusion negative tumours (logrank p<0.0001 vs. logrank p=0.4 for TMPRSS2-ERG+ tumours).Thiswas similar for the PDE4D9 score
although less pronounced compared to that of the PDE4D5 score (TMPRSS2ERG- logrank p<0.0001 vs. TMPRSS2ERG+ logrank
p<0.005). In order to predict BCR after primary treatment, we undertook ROC analysis of the logistic regression combination
model of the CAPRA score with the PDE4D5, PDE4D7, and PDE4D9 scores. For the DB cohort, this demonstrated significant
differences in the AUC between the CAPRA and the PDE4D5/7/9 regression model vs. the CAPRA and PDE4D7 risk model (AUC
0.87 vs. 0.82; p=0.049) vs. the CAPRA score alone (AUC 0.87 vs. 0.77; p=0.005).The CAPRA and PDE4D5/7/9 risk model stratified
19.2% patients of the DB cohort to either ‘no risk of biochemical relapse’ (NPV 100%) or the ‘start of any secondary treatment (NPV
100%)’, over a follow-up period of up to 15 years. Decision curve analysis presented a clear, net benefit for the use of the novel
CAPRA & PDE4D5/7/9 risk model compared to the clinical CAPRA score alone or the CAPRA and PDE4D7 model across all
decision thresholds.Conclusion. Association of the long PDE4D5, PDE4D7, andPDE4D9 transcript scores to prostate cancer patient
outcome, after primary intervention, varies in opposite directions depending on the TMPRSS2-ERG genomic fusion backgroundof
the tumour. Adding transcript scores for the long PDE4D isoforms, PDE4D5 andPDE4D9, to our previously presented combination
risk model of the combined ‘CAPRA & PDE4D7’ score, in order to generate the CAPRA and PDE4D5/7/9 score, significantly
improves the prognostic power of the model in predicting postsurgical biological outcomes in prostate cancer patients.
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1. Introduction
Prostate cancer is the most common nonhematology tumour
diagnosed in men in western countries [1, 2]. The natural
history of prostate tumours is heterogeneous with, in general,
indolent characteristics. However, it includes some forms of
the disease that can develop into deadly cancers. Disease-
specific mortality is, in particular, small for low-risk cancers
[3, 4]. This has led to a paradigm change in the management
ofmenwith low-risk profiles, as there is a considerable chance
that definitive treatment is not beneficial for these patients
but comes with the burden of adverse effects of the primary
treatment. Nevertheless, some patients with clinically low-
risk characteristics progress after initial intervention [5–7]
while others, with more advanced pathological features will
experience stable disease during periods of follow-up [8, 9].
This continues to pose the challenge of selecting the most
optimal management strategy for each individual patient.
While various national guidelines recommend considering
conservative management (i.e., active surveillance: AS) of
low-risk patients, it remains crucial to select themost suitable
patients for this regime, as discontinuation from AS, and
switching to active treatment, due to signs of progressive
disease, is common in these patient cohorts [10, 11]. Con-
sequently, more advanced protocols for inclusion/exclusion
of men to conservative management, monitoring strategies
while in AS and measures to switch to definitive treatment
are required for optimal prostate cancer patient care [12].
Signalling through the ubiquitous second messenger,
cyclic AMP (cAMP) critically impacts the functioning of all
cell types in the body. Such actions are mediated through
specific effector proteins, namely, protein kinase A (PKA)
and Exchange Protein Activated by cAMP (Epac) [14, 15].
These species are sequestered to distinct signalling com-
plexes within cells, conferring a spatial aspect that leads
to compartmentalization of signalling. The sole means of
degrading cAMP, so as to terminate cAMP signalling, is
through the action of cAMP phosphodiesterases (PDEs). In
this, the 20+ isoforms encoded by the four gene PDE4 family
(PDE4A/4B/4C/4D) play a critical role in the compartmen-
talized degradation of cAMP, as their isoform-specific N-
terminal regions contain motifs that allow for their targeting
to distinct signalling complexes [16]. PDE4D5, PDE4D7, and
PDE4D9 are a so-called long isoform as each contains both
the UCR1 and the UCR2 regulatory domains that allow for
regulation by various protein kinases, including PKA and
MK2 as well as determining the functional outcome of cat-
alytic unit phosphorylation by ERK [16]. Functionally, these
enzymes contribute to the cellular desensitization system
towards cAMP and provide nodes that enable cross-talk
between signalling pathways involving ERK, p38MAPK, and
AMPK [16].
Previously, we described the positive association of
PDE4D7 expression and the prostate-specific gene arrange-
ment between the androgen regulated transmembrane pro-
tease TMPRSS2 and the ETS transcription factor family
member ERG [17]. A study in 2005 demonstrated that
the chromosome 21 genomic fusion event TMPRSS2-ERG,
between the transmembrane protease serine 2 TMPRSS2
and the members of the ETS (erythroblast transformation-
specific) transcription factor family ERG, is common in
prostate cancer [13].The overexpression of ERG, in amajority
of prostate cancers, is driven by this fusion event, which
switches ERG to fall under the control of the androgen-driven
promotor of the TMPRSS2 gene. In a recent whole genome
sequencing study, the TMPRSS2-ERG fusion was identified
as an early event in the development of prostate cancer
[18]. However, while numerous studies have been performed,
since its discovery, the role of the TMPRSS2-ERG fusion, in
prostate cancer development and progression, is not yet fully
understood [19].
Interestingly, we did not find the same positive associa-
tion for other prostate cancer expressed long PDE4D isoform
transcripts, namely, PDE4D5 and PDE4D9. In addition,
we reported that the expression of PDE4D7 is inversely
correlated to risk of biochemical relapse after prostate cancer
surgery and, independently, adds to clinical variables and risk
scores like either CAPRA or CAPRA-S [20, 21]. The CAPRA
(Cancer of the Prostate Risk Assessment) and CAPRA-
S scores are risk models that combine either presurgical
(CAPRA) or postsurgical (CAPRA-S) score data relating to
routinely available clinical variables (PSA, Gleason score,
etc.). These models were shown to have superior power to
predict postsurgical patient outcome, either before (CAPRA)
or after (CAPRA-S) prostate operation, compared to using
the respective input variables alone [22].
Here, we set out to investigate whether we could identify
any difference in prediction of postsurgical progression risk
by PDE4D7 expression in positive vs. negative TMPRSS2-
ERG fusion prostate tumours and, whether, either PDE4D5
or PDE4D9 transcript analysis might similarly contribute
to the progression risk, as has been shown for PDE4D7
transcript analysis.
2. Patients and Methods
2.1. Patient Cohorts and Samples
2.1.1. RP (Radical Prostatectomy) Patient Cohort (n=606).
Patients consecutively managed at a single, large-volume
prostate cancer center were included in the study (Martini
Klinik, Hamburg, Germany). Two small biopsy punches
(∼1x2 mm), of a representative resected tumour area, of
patients operated on between 2000 and 2004, were collected
from the tumours index lesion.
2.1.2. RP∗ (Radical Prostatectomy∗) Patient Cohort (n=130).
Detailed characteristics of this cohort and analysis of the
respective gene expression data have been described previ-
ously [23].
2.1.3. DB (Diagnostic Biopsy) Patient Cohort (n=168). From
the tumour positive diagnostic biopsy, with the highest Glea-
son grade per patient, a single biopsy punch (∼1x2 mm) was
collected. Patients reflected those diagnosed with prostate
cancer and having undergone RP between 1994 and 2011 at
the Prostate Center (University Hospital Mu¨nster, Germany).
The local Institutional Review Boards approved the collection
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of patient tissue for clinical research, with appropriate patient
consent (for cohort design see Supplementary Figure 1).
Characteristics of this cohort have been published previously
[19].
2.2. Laboratory Methods. To account for potential tumour
heterogeneity, the two tissue punches of the RP cohort
were combined before nucleic acid extraction. A poten-
tial difference in tumour cellularity of the tissue punches
was addressed by normalization of the qPCR results of
the PDE4D transcript to four reference genes, which were
selected based on stable gene expression across multiple
tumour sample types [20]. All used molecular labora-
tory methods including oligonucleotide primers and probes
for RT-qPCR (reverse-transcriptase-quantitative PCR), RNA
extraction, and quality control and procedures are to include/
discard samples from the statistical analysis as described
before by us [20].
2.3. RNA Sequencing
2.3.1. RNA Sample Processing. 100 ng of total RNA was used
as input to remove ribosomal RNA, using Ribo-Zero Gold
(Human/Mouse/Rat) rRNA Removal Kit (Illumina Inc.),
according to the manufacturer’s instructions. For library
construction, we used the total of the depleted RNA as
input into the Scriptseq V2 RNA-Seq Library Preparation Kit
(Epicentre/Illumina Inc.). Prepared RNAseq libraries were
sequenced using NextSeq 500 sequencing system (sequenc-
ing was done by paired-end at 2 x 75 bp read length providing
approx. 80 million total reads per sample).
2.3.2. RNAseq Data Processing. The RNAseq raw data was
preprocessed using Illumina bcl2fastq software incorporating
filtering by phred scores, thereby reducing low quality reads.
Since FFPE degenerates the bases, the sequencing results
have been filtered using a scoring algorithm to select reads
representing the high-quality fraction. The final score was
calculated for a set of reads in a sample as follows. Firstly, the
set of reads was aligned against a human reference genome.
Then the alignment result, for each read (i.e., the number
of bases mapping correctly to the reference genome), was
counted per read. The total number of successfully mapped
bases was then summed over all reads of the set.This sumwas
divided by the total number of bases of the set. The resulting
relative number is called the EQ score. A score filter selects the
subset of reads that contributes to the EQ Score by virtue of a
good alignment result (all or most of the bases map correctly
to the genome). The derived subset of high-quality reads was
then selected for further processing. If reads are mapped by
fragmenting them, which may be required when aligning
RNA, the measure was calculated based on the fragments
alignment quality and the fragments selected accordingly.
2.3.3. Read Quality Filtering. To retain only high-quality
reads, the following filtering steps were applied: reads were
discarded when >50% of the bases had a phred score below
11; bases at the read ends were removed if the phred score
fell below 11; sequencing reads <63 bases and reads with
unknown (N) base calls were discarded and sequencing read
pairs were kept only if both reads passed the above described
quality filter.
2.3.4. Gene Expression Calculation. To ensure comparability
of expression values between samples all read counts were
normalized by the transcripts per million method (TPM) as
implemented in the RSEM algorithm [24].
2.4. Data Analysis and Statistics. After quality control of the
RNAseq, and the qPCR data, 536 patient samples for the RP
cohort and 151 patient samples for theDB cohort were defined
eligible for statistical analysis.
Generation of normalized PDE4D transcript expression
was performed by subtracting the RT-qPCR Cq of the
respective PDE4D transcript from the averaged RT-qPCR
Cq of the reference genes. Normalized PDE4D5, PDE4D7,
and PDE4D9 expression was transformed to the PDE4D5,
PDE4D7, and PDE4D9 scores [20]. Note that we did not
use the ΔΔCt method which is used to compare the n-
fold expression difference of a gene of interest between two
patient cohorts (e.g., treated vs. control) as we aimed to
present a score for potential future diagnostic use without
the need of a control group. In correlation analysis for
various available biological and treatment related outcomes
(Table 1) the PDE4D transcript scores were either used as
a continuous, or as a categorical variable, defined as (a)
PDE4D5/7/9 score (1≤2); (b) PDE4D5/7/9 score (>2 and
≤3); (c) PDE4D5/7/9 score (>3 and ≤4); (d) PDE4D5/7/9
score (>4 and ≤5).The CAPRA risk score and corresponding
low (1), intermediate (2), and high-risk (3) categories were
calculated as described earlier [22]. Uni- and multivariate
Cox regression and Kaplan-Meier analyses were applied to
correlate biochemical recurrence (BCR) progression free
survival, or secondary treatment (salvage radiation and or
androgen deprivation) free survival (STFS) to the PDE4D7
score in the RP cohorts (n=536), and Taylor et al. [23]; n=130)
and the DB cohort (n=151). To determine the TMPRSS2-
ERG status of patient samples in Exon Array cohorts, we
used relative ERG expression values and applied Partitioning
Around Medoids (PAM, R-package ‘cluster’, k = 2) to assign
the patient samples to the ERG positive or negative group
based on expression.Decision curve analyses were performed
as described [25]. For statistical analysis the software package
MedCalc (MedCalc Software BVBA, Ostend, Belgium) was
used.The data analysis strategy is outlined in Supplementary
Figure 2.
3. Results
3.1. Association of PDE4D Transcript Scores to Longitudinal
Clinical Outcomes Depends on the TMPRSS2-ERG Fusion
Status. Firstly, we set out to do Kaplan-Meier survival
analysis of the PDE4D7 score categories in TMPRSS2-
ERG rearrangement positive vs. gene fusion negative patient
samples. In total, we included 536 patient samples with data
on TMPRSS2-ERG status, of which we defined 280 (52.2%)
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Table 1: Aggregated summary of the characteristics of the studied patient cohorts. (A) Demographics of the radical prostatectomy (RP)
patient cohort including the 536 patients eligible for statistical data analysis. For patient age, preoperative PSA, percentage of tumour in
biopsy, prostate volume, and PSA density the min and max values in the cohort are shown; median and IQR (interquartile range) are shown
in parentheses. Pre- and postsurgical pathology is given (Note. extracapsular extension was derived from pathology stage information).
The outcome category illustrates the cumulative 5- and 10-year biochemical recurrence (BCR) and clinical recurrence to metastases (CR)
postsurgical primary treatment.The treatment category lists the cumulative 5- and 10-year start to SRT (salvage radiation therapy) or SADT
(salvage androgen deprivation therapy) after surgery. Mortality is shown as prostate cancer specific survival (PCSS) as well as overall survival
(OS) (N/A=not available). (B)Demographics of the diagnostic biopsy (DB) patient cohort. In total diagnostic needle biopsy tissues of 151 were
eligible for statistical data analysis. The demographics and clinical data of this cohort are presented equivalent to the RP cohort (N/A=not
available).
Parameter (A) RP cohort (n=536) (B) DB cohort (n=151)
Demographic & Clinical
Range (median; IQR)
Age range (at RP) 41.3-74.5 (62.5; 7.5) 47.4-77.4 (64.9; 8.5)
Preoperative PSA range 0.18-120 (7.1; 6.2) 2.0-49.1 (8.1; 5.7)
Percent tumour in biopsy range 0.2-80.0 (10.6; 20.2) N/A
Prostate Volume range 9-244 (41.0; 21.0) 13.6-148.0 (38.5; 19.2)
PSA density range 0.01-4.0 (0.17; 0.16) 0.03-1.6 (0.2; 0.17)
CAPRA Risk Category
Number of patients
(percentage)
Low Risk (CARPA 0-2) 199 (37.1%) 38 (25.2%)
Intermediate Risk (CAPRA 3-5) 273 (50.9%) 82(54.3%)
High Risk (CAPRA>5) 44 (8.2%) 31 (20.5%)
N/A 20 (3.7%) -
Pre-Surgery Pathology
Number of patients
(percentage)
Biopsy Gleason 3+3 (GG1) 282 (52.6%) 77 (51.0%)
Biopsy Gleason 3+4 (GG2) 172 (32.1%) 38 (25.2%)
Biopsy Gleason 4+3 (GG3) 46 (8.6%) 20 (13.2%)
Biopsy Gleason >=4+4 (>=GG4) 36 (6.7%) 16 (10.6%)
cT1 348 (64.9%) 97 (64.2%)
cT2 175 (32.6%)
cT3 13 (2.3%) 54 (35.8%)
N/A 1 (0.2%) -
Post-Surgery Pathology
Number of patients
(percentage)
Pathology Gleason 3+3 (GG1) 176 (32.8%) 46 (30.5%)
Pathology Gleason 3+4 (GG2) 268 (50.0%) 52 (34.4%)
Pathology Gleason 4+3 (GG3) 69 (12.9%) 31 (20.5%)
Pathology Gleason >=4+4 (>=GG4) 23 (4.3%) 22 (14.6%)
pT2 312 (58.2%) 88 (58.3%)
pT3 224 (41.8%) 63 (41.7%)
pT4 0 (0%) 0 (0%)
Positive Surgical Margins 197 (36.8%) 33 (21.9%)
Extra-Capsular Extension (=T3a) 139 (25.9%) 37/151 (24.5%)
Seminal Vesicle Invasion 87 (16.2%) N/A
Lymph Node Invasion 17 (3.2%) 10 (6.6%)
Follow-up
(months)
Mean 105.1 73.7
Median 120.2 73.6
Outcome–
Number events/total
patient number
(percentage)
BCR within 5 years 169/480 (35.2%) 45/151 (29.8%)
BCR within 10 years 210/402 (52.2%) -
CR within 5 years 46/472 (9.7%) 4/151 (2.6%)
CR within 10 years 61/337 (18.1%) -
Salvage Treatment –
Number events/total
patient number
(percentage)
SRT within 5 years 130/475 (27.4%) 12/151 (7.9%)
SRT within 10 years 164/381 (43.0%) -
SADT within 5 years 75/467 (16.1%) 16/151 (10.6%)
SADT within 10 years 110/350 (31.4%) -
Survival–
Number events/total
patient number
(percentage)
PCSS within 5 years 13/453 (2.9%) 1/151 (0.7%)
PCSS within 10 years 25/304 (8.2%) -
OS within 5 years 25/465 (5.4%) 1/151 (0.7%)
OS within 10 years 51/331 (15.4%) -
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as fusion positive, while 256 samples (47.8%) were defined
to be absent of this prostate-specific gene fusion event.
We selected biochemical recurrence (BCR) as a surrogate
endpoint for postsurgical disease progression, due to the
significant number of events for this outcome in our studied
patient cohorts (Table 1).
We observed a clear difference in BCR progression, free
survival analysis between the fusion positive vs. negative
tumours with a highly significant logrank p (<0.0001) for
the PDE4D7 categories in the presence of the rearranged
TMPRSS2-ERG gene fusion (Figure 1(a)). The patient group
with the highest level of PDE4D7 expression (i.e., PDE4D7
scores 4-5) showed lowest risk of disease progression after
surgery in the TMPRSS2-ERG fusion positive cancers. In
contrast, in prostate tumours without an ERG gene fusion
event, the discrimination in Kaplan-Meier survival between
the defined four different PDE4D7 categories was nonsignif-
icant (logrank p = 0.08; Figure 1(b)). Interestingly, when
looking at BCR progression free survival analysis of the
PDE4D5 score we found the opposite situation compared to
what we observed for the PDE4D7 score. Only in gene fusion
free tumours did the PDE4D5 score categories significantly
(logrank p<0.0001) predict biochemical relapse (Figures 1(c)
and 1(d)). We observed a similar result to this for the
PDE4D9 score categories with a logrank p<0.0001 in survival
analysis in TMPRSS2-ERG negative tumours. However, in
contrast to the analysis of PDE4D5 scores, the survival
analysis of PDE4D9 score categories in gene fusion positive
cancers resulted in a significant association with biochemical
recurrence, although with a somewhat weaker p compared to
the TMPRSS2-ERG negative tumours (logrank p=0.005 vs.
logrank p<0.0001, respectively; Figures 1(e) and 1(f)).
Next, we investigated to what extent the score categories
for the three different prostate cancer expressed PDE4D
transcripts were determined to be mutually exclusive in indi-
vidual patient samples or, whether, the same score category
(e.g., [1, 2] or [4, 5]) was seen across the same samples
for the three long form PDE4D splice variants we analysed
here. For this we plotted a heatmap that included all 536
patient samples, with an initial split between TMPRSS2-
ERG gene fusion negative (Figures 2(a) and 2(b)) vs. fusion
positive (Figure 2(c)) samples. While the samples within the
TMPRSS2-ERG negative samples were ordered according to
their PDE4D5 or PDE4D9 score category (Figures 2(a) and
2(b), respectively) the samples that were positive for the gene
fusion were found to order according to their PDE4D7 score
category from low to high (Figure 2(c)). The heatmaps repli-
cated the results of the Kaplan-Meier survival analysis, with
more events in the lower PDE4D isoform score categories
(Figures 2(a)–2(c)). However, as can be appreciated, the
PDE4D transcript score categories are, to some extent, non-
overlapping within a patient sample. When focusing on the
lowest score category (i.e., all scores for PDE4D5/4D7/4D9
between score 1 and score 2) we identified 31 samples with
at least one of the three PDE4D transcripts with a score
category between score 1 and score 2 (Figure 2(d)). For three
samples (marked in bold red) we measured the lowest score
category for all three of these long form PDE4D transcripts
while for two samples (marked in bold blue) at least two
PDE4D transcripts belonged to the lowest score category.
For the other 26 samples only one PDE4D splice variant was
expressed at very low levels (i.e., score between 1 and 2), while
the two other isoforms showed higher expression levels in
these samples. The risk, of either developing metastases or
dying from prostate cancer (6 and 5 out of the 31 patients,
respectively), increases strongly with reduced expression
levels of multiple prostate-expressed long PDE4D isoforms
(Figure 2(d)). Also, the time scale after surgery, to an event
like BCR, was generally shorter (<2 years) for those patients
having at least two low PDE4D transcript scores (between
either scores 1-2 and/or scores 2-3). Vice versa, the higher
the expression level of at least one of the three PDE4D splice
variants, the less likely was the chance of the patient in
experiencing BCR after surgery. However, in instances where
such an event occurred, it was typically on a longer time
scale (2-5 years and, in some cases, >5 years after primary
treatment).
Taken together, these data indicate that next to PDE4D7
transcript analyses, analysis of transcript levels of the long
PDE4D5 and PDE4D9 isoforms may also have significant
prognostic value in prostate cancer. Therefore, we hypothe-
sized that the addition of the PDE4D5 and PDE4D9 scores, to
that of the PDE4D7 score,might increase the power to predict
postsurgical risk of disease progression, either over various
clinical variables or over the previously reported prognostic
PDE4D7 model [13, 19].
3.2. Logistic Regression Model of Clinical Variables and
Prostate Cancer Expressed Long PDE4D Transcripts. To test
this concept, we developed a prognostic model to include
the clinical CAPRA score [22] together with the transcript
scores for the PDE4D5, PDE4D7 and PDE4D9 long isoforms.
For model development we used the RP (n=536) and RP∗
cohorts (n=130).We performed logistic regression analysis to
predict postsurgical biochemical relapse in the RP and RP∗
cohorts in order to estimate the weights for the CAPRA score
as well as for the PDE4D transcripts. The coefficients were
calculated by logistic regression. Next, we adjusted the initial
coefficients, after logistic regression analysis, of the four
model inputs on the RP∗ cohort by calculating an average
of the coefficients for the RP and RP∗ cohorts, thus taking
the heterogeneity of different patient groups into account.
The final CAPRA& PDE4D5/7/9 model (co1∗PDE4D5 score
+ co2∗PDE4D7 score + co3∗PDE4D9 score + co4∗CAPRA
score; Supplementary Table 1) was tested for its prognostic
power to predict BCR, as well as start of secondary treatment
after surgery (i.e., radiation, or hormone deprivation), in the
independent DB patient cohort. For any other outcome, such
as eithermetastases or death, we used theRP andRP∗ cohorts
(note: these clinical endpoints were not used during model
development).
3.3. Kaplan-Meier Survival Analysis of the CAPRA &
PDE4D5/7/9 Model. In Kaplan-Meier survival analysis the
CAPRA & PDE4D5/7/9 model stratified 29 men (19.2%)
of the total cohort (n=151) within the lowest score class
(between scores 1-2) into a patient group with no risk over
the follow-up period of 60 to 200 months of PSA relapse, nor
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Figure 1: Continued.
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Figure 1: Kaplan-Meier survival analysis of the time to PSA relapse (endpoint BCR: biochemical recurrence) in the RP patient cohort (n=536)
for the PDE4D5, PDE4D7, and PDE4D9 scores. (a) Kaplan-Meier analysis of the BCR free survival of the PDE4D7 score in TMPRSS2-ERG
positive tumours (n=280). (b) Kaplan-Meier analysis of the BCR free survival of the PDE4D7 score in TMPRSS2-ERG negative tumours
(n=256). (c) Kaplan-Meier analysis of the BCR free survival of the PDE4D5 score in TMPRSS2-ERG positive tumours (n=280). (d) Kaplan-
Meier analysis of the BCR free survival of the PDE4D5 score in TMPRSS2-ERG negative tumours (n=256). (e) Kaplan-Meier analysis of the
BCR free survival of the PDE4D9 score in TMPRSS2-ERG positive tumours (n=280). (f) Kaplan-Meier analysis of the BCR free survival of
the PDE4D9 score in TMPRSS2-ERG negative tumours (n=256). Censored patients are indicated by vertical bars. PDE4D5, PDE4D7, and
PDE4D9 score categories were defined as PDE4D5/7/9 (1-2): PDE4D5/7/9 scores (1 to <2); PDE4D5/7/9 (2-3): PDE4D5/7/9 scores (2 to <3);
PDE4D5/7/9 (3-4): PDE4D5/7/9 scores (3 to <4); PDE4D5/7/9 (4-5): PDE4D5/7/9 scores (4 to <=5).
any risk of starting secondary treatments (Figures 3(a) and
3(b)).
By slightly increasing the cut-off of this model score
category from (scores 1-2) to (scores 1-2.1), the number
of men in this group with no risk of postsurgical disease
progression increased from 29 to 36 subjects (23.8%; data not
shown). In contrast, the patient with the highest categories of
CAPRA & PDE4D5/7/9 scores of (score 3-4 and (score 4-5)
experience a risk of biochemical progression within 5 years
after surgery of 63.9% and 83.3%, respectively. Similarly, the
risk of undergoing secondary treatment was estimated from
the survival analysis, within a period of 5 years post-surgery,
as 44.1% and 75% for these two patient groups, respectively
(Figures 3(a) and 3(b)).
3.4. ROCCurve Analysis of the CAPRA&PDE4D5/7/9Model.
For the DB cohort (as above), we iused BCR and start of
secondary therapy as clinical outcomes. Thus, we compared
the CAPRA & PDE4D5/7/9 model with the, previously
presented, CAPRA&PDE4D7model [21]. For both we tested
clinical endpoints, identifying an increase in the AUC (Area
Under the Curve) of 10% and 6%, respectively, compared to
the CAPRA score alone, and 5% and 4%, respectively, for the
CAPRA & PDE4D7 model (Figures 3(c) and 3(d)).
To further explore this, we tested outcomes other than
biochemical relapse. Aswe developed the combinationmodel
of the CAPRA and the PDE4D transcript scores, using BCR
as an endpoint in the two radical prostatectomy cohorts
(RP and RP∗), we did not test the model on that end-
point in these cohorts. Instead we used other outcomes
for evaluation, namely the progression to metastases after
surgery or death from prostate cancer after primary (i.e.,
RP), or secondary, treatments (i.e., SRT: salvage radiation
therapy; SADT: salvage androgen deprivation therapy), to
investigate any potential added value of combining PDE4D5
and PDE4D9 transcript scores with our previous CAPRA
and PDE4D7 model. Table 2 provides an overview of the
increase in AUC’s (areas under the curves) of up to 12%, and
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Figure 2: (a)Heatmap of TMPRSS2-ERG negative tumour samples of the RP cohort (n=256); samples are ordered according to their PDE4D5
score from low to high. (b) Heatmap of TMPRSS2-ERG negative tumour samples of the RP cohort (n=256); samples are ordered according
to their PDE4D9 score from low to high. (c) Heatmap of TMPRSS2-ERG positive tumour samples of the RP cohort (n=280); samples are
ordered according to their PDE4D7 score from low to high. The legends of the graphs and color coding are defined as ‘Sample ID’: IDs of
the 256 TMPRSS2-ERG negative tumour samples of the RP cohort. ‘TMPRSS2-ERG status’: presence (dark green) or absence (light green)
of the gene fusion event in a given sample. ‘BCR class’: every patient is coded for the presence (dark yellow) or absence (light yellow) of a
BCR (biochemical recurrence) event during the >120 months median follow-up. ‘Metastasis class’: every patient is coded for the presence
(dark orange) or absence (light orange) of a metastases event during the >120 months median follow-up). ‘PCa death class’: every patient is
coded for the presence (dark red) or absence (light red) of a prostate cancer specific death event during the >120 months median follow-up.
PDE4D5, PDE4D7, and PDE4D9 score categories were defined as PDE4D5/7/9 (1-2): PDE4D5/7/9 scores (1 to <2; dark blue); PDE4D5/7/9
(2-3): PDE4D5/7/9 scores (2 to <3; light blue); PDE4D5/7/9 (3-4): PDE4D5/7/9 scores (3 to <4; light pink); PDE4D5/7/9 (4-5): PDE4D5/7/9
scores (4 to <=5; dark pink). (d) RP cohort patient samples (n=31) with the lowest PDE4D5, PDE4D7, and PDE4D9 scores. The legends of
the graph and color coding are defined as above with the change of a color coding for BCR, Metastasis, and PCa Death class according to a
time interval to the event; light yellow: no event during >120 months median follow-up; light blue: <2 years to the event during >120 months
median follow-up; light grey: 2-5 years to the event during >120 months median follow-up; light green: >5 years to the event during >120
months median follow-up.
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Figure 3: (a) Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival in the diagnostic biopsy patient (DB) of the categorized
CAPRA and PDE4D5/7/9 combination score. (b) Kaplan-Meier analysis of the postsurgical of secondary treatment free survival (STFS) time
in the diagnostic biopsy patient (DB) cohort of the categorized CAPRA & PDE4D5/7/9 combination score. The CAPRA and PDE4D5/7/9
combination model was developed by logistic regression using data of the RP and RP patient cohort and used as such for testing in the DB
patient cohort. The model score was transformed into a CAPRA & PDE4D5/7/9 score distribution between 1 and 5 equivalent to how the
individual PDE4D transcript scores were generated [13]. Censored patients are indicated by vertical bars. PDE4D5/7/9 score categories were
defined as PDE4D5/7/9 (1-2): PDE4D5/7/9 scores (1 to<2); PDE4D5/7/9 (2-3): PDE4D5/7/9 scores (2 to<3); PDE4D5/7/9 (3-4): PDE4D5/7/9
scores (3 to<4); PDE4D5/7/9 (4-5): PDE4D5/7/9 scores (4 to<=5). (c) ROC curve analysis of 5-year biochemical recurrence in the DB cohort
(n=151) of theCAPRA score (orange curve;AUC=0.77) vs. the CAPRA and PDE4D7 (green curve;AUC=0.82) vs. the CAPRA&PDE4D5/7/9
(blue curve; AUC=0.87) logistic regression models. (d) ROC curve analysis of 5-year postsurgical secondary treatment free survival in the
DB cohort (n=151) of the CAPRA score (orange curve; AUC=0.76) vs. the CAPRA and PDE4D7 (green curve; AUC=0.78) vs. the CAPRA
and PDE4D5/7/9 (blue curve; AUC=0.82) logistic regression models.
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Table 2: Overview of the AUCs for the CAPRA score, the CAPRA and PDE4D7, and the CAPRA and PDE4D5/7/9 regression models to
predict multiple endpoints in various patient cohorts. The patient cohort that was used for the respective endpoint is indicated including the
number of patients with respective follow-up periods. The tested clinical endpoints are given including the number and percentage of the
respectively tested events.Note.The CAPRA score is calculated based on [23]; however, as the information on the number of positive biopsy
cores was missing for the RP∗ cohort the CAPRA score for this cohort was calculated using patient age, pre-operative PSA, biopsy Gleason
score, and clinical stage only. The influence of the missing information on the biopsy cores was very limited as tested on the RP as well as the
DB cohort (data not shown).
Patient Cohort Tested Clinical Endpoint(post treatment) # events
CAPRA&PDE4D5/7/9
Score
CAPRA&PDE4D7
Score
CAPRA
Score
AUC
RP∗ (n=130) metastases (post-surgery) 8 (6.2%) 0.86 0.82 0.74
DB (n=151) 5-yr PSA recurrence (post-surgery) 45 (19.8%) 0.87 0.82 0.77
DB (n=151) 5-yr start of secondary treatment(post-surgery) 27 (17.9%) 0.82 0.78 0.76
RP (n=220) 10-yr prostate cancer death(post-surgery) (pGleason >6) 21 (11.1%) 0.78 0.78 0.74
RP (n=86) 10-yr prostate cancer death (post-SRT) 18 (20.9%) 0.78 0.76 0.7
RP (n=61) 10-yr prostate cancer death (post-SADT) 17 (27.9%) 0.74 0.72 0.67
up to 12%, comparing the use of either the CAPRA score,
the CAPRA and PDE4D7 score model, or the CAPRA and
PDE4D5/7/9 score model. These data indicate that the use of
additional prostate relevant long formPDE4D transcripts can
increase the prognostic power of our previously published
combination model of the CAPRA and PDE4D7 score.
3.5. Decision Curve Analysis of the CAPRA and PDE4D5/7/9
Model. Decision curve analysis is a net benefit analysis that
compares the true-positive to the weighted false-positive
rates across different risk thresholds that a clinician/patient
might want to accept [26]. We explored the net benefit of
avoiding primary treatment, based on the predicted risk
of a PSA relapse after surgery for the CAPRA score by
comparing the utility of the CAPRA and PDE4D7 model
versus the CAPRA and PDE4D5/7/9 combination model.
Such an analysis demonstrated that both or our models
showed better net benefit compared to the “treat all” strategy,
while the CAPRA and PDE4D5/7/9 combination model
provided the best net benefit across all modeled decision
thresholds (Figure 4(a)). Similarly, the net reduction analysis
in primary treatment revealed a substantial difference in
treatment reduction between using the CAPRA score alone
and theCAPRA and PDE4D5/7/9 combinationmodel, across
all decision thresholds (Figure 4(b)). Thus, the addition of
PDE4D5 and PDE4D9 scores to the CAPRA and PDE4D7
model clearly improves the net benefit in decision curve
analysis. Importantly, it provides a potential means of more
effectively reducing the number of interventions per 100
patients compared to either the CAPRA model alone or the
CAPRA and PDE4D7 combination model.
Thus, herewe demonstrate that our previously formulated
CAPRA and PDE4D7 risk model can be further improved by
adding scores for the long PDE4D5 and PDE4D9 transcripts
into the model.The rationale for this added prognostic bene-
fit of PDE4D5 and PDE4D9 is supported by the differences in
prediction power between TMPRSS2-ERG positive vs. gene
fusion negative patient tumours. Thus, by complementing
PDE4D7 with the two other prostate cancer-relevant PDE4D
transcripts, namely, PDE4D5 and PDE4D9, we have formu-
lated a more effective prognostic model that has potential
for assessing the risk of disease progression before primary
intervention in prostate cancer.
4. Discussion
We have previously proposed that a predictive model of
the clinical risk algorithm CAPRA, in combination with
the prostate cancer biomarker PDE4D7, provides value to
prostate cancer risk stratification [20, 21]. Although we were
able to demonstrate that PDE4D7 transcript analysis adds
independent value to the clinical CAPRA model and signifi-
cantly improves the prognostic power to predict postsurgical
disease progression, we set out here to see if there was a way
to increase further the value of this CAPRA and PDE4D7
combination model. In our previous work we identified
expression differences of various long PDE4D isoforms in
primary tumour material that were different for the prostate
cancer specific TMRPSS2-ERG gene rearrangement [27].
However, due to limited number of patients and progres-
sion events we were not able to investigate whether this
phenomenon might also translate into differences of risk
prediction subject to the presence or absence of the genomic
variation.
Here, however, we have been able to dissect the impact
of three different PDE4D transcripts, namely those for the
PDE4D5, PDE4D7, and PDE4D9 long isoforms, on the
risk of postsurgical disease progression, depending on the
genomic background of the patient’s tumour. Interestingly,
PDE4D7 was found to be associated significantly with post-
treatment disease recurrence in a TMRPSS2-ERG fusion
positive background, while being of reduced prognostic value
in patients without this particular gene fusion event. In
contrast PDE4D5 and PDE4D9 transcript levels proved to
be highly prognostic in a non-fusion genomic background,
while PDE4D9was less so. AndPDE4D5was not significantly
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Figure 4: (a) Decision curve analysis in the diagnostic biopsy (DB) patient cohort of the net benefit of five different treatment decision
strategies (treat all, treat none, treat based on the CAPRA score, treat based on the CAPRA and PDE4D7 score, treat based on the CAPRA
and PDE4D5/7/9 score) for men at risk of disease recurrence within 5 years after surgery. In total 45 of the 151 investigated patients failed
the initial primary treatment of surgery by PSA recurrence (29.8%) within 5 years after intervention. Treatment strategies were tested for
their net benefit across indicated threshold probabilities (0.05 step size) to trigger prostate surgery based on the probability of future disease
recurrence.The CAPRA scores, the CAPRA and PDE4D7 scores, and the CAPRA and PDE4D5/7/9 scores were converted into 5-year BCR
probabilities with logistic regression on the BP cohort (n=151 men with completed 5-year follow-up) before estimating net benefit. (b) Net
reduction analyses demonstrating in how many patients a resection can be avoided based on the predicted risk of BCR derived from the
CAPRA score and the CAPRA and PDE4D7 and CAPRA and PDE4D5/7/9 scores, respectively.
associatedwith disease progressionwhen theTMRPSS2-ERG
genomic fusion event was present.
Lately, multiple genomics studies have identified the
PDE4D gene as a putative genomic driver/suppressor gene
of (prostate) cancer [18, 28, 29]. Indeed, one of these studies
even identified differences in the evolution of TMPRSS2-
ERG+ vs. TMPRSS2-ERG− prostate cancers, based on whole
genome sequencing of 112 primary and metastatic prostate
tumours [29]. While in ERG+ rearranged tumours, the
earliest homozygous deletions appeared in region chr5:55-
59 Mb in ERG− cancers, losses at chr5:60-100 Mb, cov-
ering the well-known affected gene CHD1, were reported.
Intriguingly, exon 1, as well as exons 1-3, which specifi-
cally encode the isoform-specific N-terminal portions of
PDE4D5 and PDE4D7, respectively, is located between the
region chr5:59-60 Mb. The differences in genomic rear-
rangement, as described for chromosome 5, in the different
TMPRSS2-ERG fusion background may explain, to some
extent, the variability in PDE4D long transcript expression,
as described by us earlier [27]. In this study we have exploited
and extended this to allow for the PDE4D long isoform-
specific prognosis of postsurgical risk of disease progres-
sion.
Active surveillance (AS) has become an accepted treat-
ment alternative and is recommended by the national guide-
lines for men with low- and very-low risk prostate cancer
[30]. The guiding principle of AS is to delay, not to avoid, the
primary treatment. The switch fromAS to active intervention
should be taken while the treatment intent is still curative.
Consequently, men in AS have to follow strict monitoring
schedules as discontinuation and switch to active treatment
takes place at the earliest sign of disease progression, such
as a rise in PSA, a biopsy Gleason score, or clinical stage
migration. Recently, the 10-year outcomes of the ProtecT trial
were published [31]. The aim of this randomized controlled
trial, which was started in the early 2000 and involving
multiple clinical sites across the UK, was to evaluate the effec-
tiveness, cost-effectiveness, and acceptability of treatments
(i.e., active monitoring vs. active intervention) for men with
localised prostate cancer. Disease-specific mortality was low
in all treatment arms of the trial. Moreover, the authors could
not conclude, at median follow-up of 10 years, a significant
difference in prostate cancer mortality, irrespective of the
treatment assigned [31]. Taking the low mortality risk of
men in the active monitoring arm of the ProtecT trial
into consideration, it is questionable as to what extent the
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observed changes in clinical presentation of the disease, in an
AS setting, correlateswith true biological disease progression.
Currently, new technology such as either multi-paramet-
ric MRI or genomics, is being considered for stratification of
men to AS or for monitoring of men in AS [32, 33]. While
the longitudinal cost of AS has been estimated to reach the
same order ofmagnitude as for various primary interventions
[34] together with the cost of repeated biopsies, in particular
[35], any newly implemented technical tool might only be
cost-effective if its use will lead to less men discontinuing AS
and facilitating decisions that allow for a switch to definitive
treatment and/or significantly reduced surveillance schedules
(or even avoided in some patients).
Wepropose that the combination of a clinicalmetric, such
as the CAPRA score, together with genomic biomarkers such
as those presented here, namely evaluation of PDE4D5/7/9
long form transcripts, offer a potentially highly effective
means for predicting the future risk of a patient to experience
disease progression. Such an approach then may provide
future support for selecting patients to be included into
modified AS regimens that require, compared to current
regimens, a very much reduced requirement for follow-up
studies over pre-defined time periods after the start of AS.
5. Conclusions
We demonstrate that the prognostic power of analysing
the presurgical CAPRA score together with the prostate
cancer biomarker PDE4D7 (CAPRA and PDE4D7) can be
significantly improved by adding in analyses of transcript
level scores for long PDE4D isoforms PDE4D5 and PDE4D9,
providing a novel risk model (CAPRA and PDE4D5/7/9).
The AUC of the base model of the CAPRA score alone was
increased by 10%, from 0.77 to 0.87, when combined with
all three prostate cancer relevant long PDE4D transcripts
into a single risk prediction algorithm. The resulting risk
score is positively correlated with increasing risk of post-
surgical disease progression. The patient group with lowest
risk score category, as defined here, represents the lowest
possible progression risk within the validation cohort with
no events occurring during the examined period of follow-
up. In contrast, the patient group within the highest risk
score category experiences a close to 100% probability of
experiencing disease progression after primary therapy.
6. Limitations
The retrospective nature of this study provides a potential
limitation in the interpretation of the results towards a
prospective setting. Furthermore, all study patients were
undergoing surgery as a primary treatment. Patient outcomes
in terms of the investigated disease progression endpoints
might have been influenced by the applied treatment which
limits the interpretation towards and active surveillance
setting.
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Supplementary Materials
Supplementary Figure 1. Summary overview of the design
of the two patient study cohorts. (A) Design of the radical
prostatectomy (RP) cohort. Patients were operated at the
Martini Klinik, Hamburg, Germany, between 2000 and 2004.
(B) Design of the diagnostic biopsy (DB) cohort. Patients
were operated at the University Hospital Muenster, Ger-
many between 1994 and 2011. For clinical characteristics of
the patient cohorts, see Table 1 in the main manuscript.
Supplementary Figure 2. Analysis design of the generated
PDE4D5/7/9 score data in the two patient study cohorts. The
surgery cohort (RP) included 606 patients of which 536 were
eligible for statistical data analysis after quality control of the
RT-qPCR and the RNAseq data and after removal of patients
with adjuvant and neo-adjuvant hormone therapy before or
after surgery. The RP∗ cohort (Taylor et al., 2010) consisted
of 178 patients of which 130 patients were included into
this study. The diagnostic biopsy (DB) cohort comprised 168
patients of which 151 were eligible for statistical data analysis
after quality control of the RT-qPCR data. For characteristics
of the patient cohorts see Table 1 in the main manuscript.
Supplementary Table 1. The CAPRA∗ and PDE4D579 score
combination model was developed by logistic regression of
the CAPRA score and the normalized PD4D5, PDE4D7, and
PDE4D9 expression values in the RP patient cohort (n=480
with completed 5-years follow-up after surgery) and in the
RP∗ cohort (n=130; Taylor et al., 2010).The logistic regression
coefficients for the two cohorts were averaged to generate a
mean coefficient for PD4D5, PDE4D7, and PDE4D9 and the
CAPRA score based on the data of two independent patients
cohorts in order to take the variation of different patient
groups into account. These coefficients were used as weights
in the final CAPRA and PDE4D579 regression model. Note.
The CAPRA score is calculated based on Cooperberg and
al., 2005; however, as the information on the number of
positive biopsy cores was missing for the RP∗ cohort such
that the CAPRA score for this cohort was calculated using
only patient age, preoperative PSA, biopsy Gleason score, and
clinical stage.The influence of themissing information on the
biopsy cores was very limited as tested on the RP as well as the
DB cohort (data not shown). (Supplementary Materials)
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